Aankondiging • May 19
Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026 Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026 Aankondiging • Feb 26
Elekta AB (publ), Annual General Meeting, Sep 03, 2026 Elekta AB (publ), Annual General Meeting, Sep 03, 2026. Aankondiging • Jan 23
Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026 Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation. Aankondiging • Jan 16
Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear Accelerator Elekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities. Aankondiging • Aug 28
Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026 Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter.
The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year. Aankondiging • May 29
Elekta AB (publ), Annual General Meeting, Sep 04, 2025 Elekta AB (publ), Annual General Meeting, Sep 04, 2025. Aankondiging • May 05
Elekta Announces Use of Its 1.5T Elekta Unity MR-Linac Elekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues. Aankondiging • Nov 01
Caroline Leksell Cooke Steps Down from Elekta AB's Board of Directors Elekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member. Aankondiging • Sep 27
Elekta AB Submits Elekta Evo to U.S. FDA for Premarket Approval Elekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union. Aankondiging • Sep 06
Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, Respectively Elekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively. Aankondiging • Jul 06
Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025 Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025 Aankondiging • Jun 06
Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025 Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025 Aankondiging • Mar 02
Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the Board Elekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role. Aankondiging • Feb 29
Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024 Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024 Aankondiging • Nov 01
Elekta AB (publ) Announces Composition of Nomination Committee Elekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds. Aankondiging • Oct 24
Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD). Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24. Aankondiging • Oct 13
Elekta AB (publ), Annual General Meeting, Sep 05, 2024 Elekta AB (publ), Annual General Meeting, Sep 05, 2024. Aankondiging • Jun 30
Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ) Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company. Aankondiging • May 13
Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONE Elekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience. Aankondiging • Feb 14
Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter. Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024. Aankondiging • Nov 24
Elekta AB (publ), Annual General Meeting, Aug 24, 2023 Elekta AB (publ), Annual General Meeting, Aug 24, 2023. Aankondiging • Nov 19
Elekta Introduces Elekta Studio with Its Launch of the ImagingRing Elekta introduced Elekta Studio with its launch of the ImagingRing, an advanced interventional CT system that revolves around the patient and enables clinicians to conduct the entire brachytherapy workflow - including applicator /needle insertion, imaging, planning and treatment delivery - without moving the patient from room to room. Elekta Studio was designed to radically simplify the 3D image-guided adaptive brachytherapy workflow and increase patient comfort. The ImagingRing is mobile, so it can be transported throughout the hospital to any desired location. A conventional CT, whether stationary or mobile, cannot offer real-time imaging nor the access to the patient as the ImagingRing does with its sleek design. With the ImagingRing, no time has to be spent moving the patient from the treatment table to the CT and back, so applicator displacement is avoided, increasing treatment accuracy and patient comfort. In addition, since the ImagingRing is at the heart of the Elekta Studio, system transport and waiting times for an imaging slot - such as for a traditional CT scan - are eliminated, thus accelerating the workflow. Aankondiging • Sep 26
Elekta Early Out in Securing MDR Certificates for Its Linac Portfolio Elekta announced it has received the EU Medical Device Regulation (EU MDR) certificate for its linear accelerator (linac) portfolio. More than 4,000 Elekta linacs are currently clinical around the world, treating patients with a wide variety of cancers. The MDR certificate applies to the following products, including their components and accessories: Versa HD™; Elekta Synergy; Elekta Infinity. The EU MDR, ratified in May 2017, will become effective in May 2021, followed by a transition period until May 2024. Its purpose is to ensure that medical devices are introduced to and sold on the market within a robust, transparent and sustainable regulatory framework. Maurits Wolleswinkel, President Linac Solutions at Elekta, adds: "As a leading medical device company, we're proud that Elekta is among the first to guarantee that its customers will be able to continue offering their patients advanced cancer treatment without interruption. More importantly, it supports Elekta's promise to make quality radiation therapy accessible to all, especially during the Covid-19 pandemic." Elekta will continue its certification program to ensure that its advanced precision radiation medicine portfolio will be fully compliant during the MDR transition period. Aankondiging • Aug 26
Elekta AB (publ) to Report Fiscal Year 2021 Results on May 27, 2021 Elekta AB (publ) announced that they will report fiscal year 2021 results at 5:39 AM, GMT Standard Time on May 27, 2021 
